The overall objective of Innovest Global’s Biotechnology and Health Services is to acquire unique operating, and cutting-edge technology companies in the Biotechnology, Medicine and Health & Wellness markets in order to increase the value of Innovest. The recent past and present has shown us that technology combined with health and medicine has revolutionized the way in which we live our lives and has improve our living condition for the individual and public health in general. Innovest Global seeks to synergize its expertise in marketing, sales and business development with leading and cutting-edge companies in biotechnology and medicine in order to deliver the world’s best healthcare and significant long-term financial growth for its shareholders.
We seek to target companies with growing operations or novel technologies in the medical and health and wellness markets, including but not limited to Digital Health, Medical Devices and Stem Cell Technology. We will grow this division through existing partnerships and networks within the private sector, National Institutes of Health, academic institutions, hospitals and incubators that have companies and/or products in the market and/or in the Research & Development phase about to enter markets. Innovest Global will provide the leadership and expertise to promote growth of these companies and continued success in the market place through resources and financial leadership. The partnerships will also support logistics for completions of R&D of new technology and competitive entry into market.
StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells.
STEMVAX RELIES ON CUTTING-EDGE RESEARCH AND CREATIVITY TO FACE THE UNKNOWN